1.. INTRODUCTION
================

Patients with complex fracture patterns receive internal fixation with increasing frequency, as these cannot be stabilized sufficiently with conservative treatment means, nor do displaced bone structures remodel into functional anatomy (e.g. at the mandibular angle and condyle) \[[@R1],[@R2]\]. Stainless steel and titanium miniplate osteofixation, or commonly called "titanium-osteosyntheses", have several drawbacks, such as potential growth disturbance, passive migration, palpability and corrosion. Metallic debris, arising from corrosion, enters local lymphatic nodules, causing local irritation, dysesthesia, temperature sensitivity, pain, infection, and interference with diagnostic and therapeutic radiation \[[@R3],[@R4]\]. Bone weakening has been observed, and this is caused by local stress-shielding of rigid mandibular and extremity plate osteofixations \[[@R3],[@R5],[@R6]\]. This is why operative removal in a second operation is necessary and recommended. A second operation can be avoided, however, by using resorbable osteofixations.

Given sufficient stability, a resorbable osteofixation increases the load placed on healing bone through progressive degradation \[[@R4],[@R7]-[@R9]\]. Complete disintegration is sought after 3 months of stable fixation and should cause no local irritation of tissues \[[@R9],[@R10]\]. The biodegradation of polymers used in resorbable osteofixations has been demonstrated in many laboratory *in-vitro* and *in-vivo* animal studies \[[@R11]-[@R16]\], but only few *in-situ* patient studies have been reported \[[@R17],[@R18]\]. These latter studies have some limitations, such as small number of explants and the results being applicable only to the specific polymer used for fabricating the osteosyntheses. This suggests that degradation studies need to be conducted on a polymer-by-polymer basis \[[@R9],[@R10],[@R19]-[@R21]\].

Studies of crystalline poly(L-lactide) (PLLA) have shown, that molecular weight, crystallinity, and melting point remained constant after 2 years *in vitro*, indicating slow, if not incomplete degradation \[[@R19],[@R21]\]. Crystalline polyglycolide (PGA) has been reported to degrade significantly faster than PLLA \[[@R19]\]. Both of these polymers have been implicated in clinically apparent foreign-body reactions in patients \[[@R22]\], but not in animals \[[@R22]\]. *In-vitro* (laboratory experimentation) or *in-vivo* (laboratory animals) results showed limited transferability to the *in-situ* that means the "*in-patient*" situation. For example, test protocols for an accelerated *in-vitro*"aging" of the implants can result in degradation pattern that are not representative for the *in-situ*situation (Landes / Jaeger, unpublished results) Copolymers of PLLA with PGA (PLGA) combine the benefits of both materials --- that is, the adequate strength retention of PLLA and the relatively fast degradation rate of PGA. In a previous report we showed that in patients, implants fabricated from a 85%mole:15%mole PLGA copolymer degrade considerably faster *in-situ*, than those fabricated from a 70%mole:30% mole P(L/DL)LA (racemic mix of L and DL lactide) copolymer. Both copolymers degrade reliably *in-situ*, mainly by hydrolysis, but at a rate that is slower than what occurs *in-vitro*\[[@R18]\]. The exact moment of total resorption can only be extrapolated from the degradation data of explants and the macroscopic absence of material in patients on surgical revision \[[@R18]\]. Three point bending test (explants were too small) and scanning electron microscopy were not performed at that time.

In the present work, we investigated the fatigue performance and degradation characteristics of a new generation of resorbable osteofixation, fabricated from a new copolymer, poly(70%moleL-lactide-co-24%moleDL-lactide)-6%mole trimethylane-carbonate (PLDLLA-TMC) in patients. This polymer has the advantage to be less brittle in handling, due to the addition of TMC. In 2.5 mm strength, PLDLLA-TMC is also more stable than other available polymer osteofixations \[[@R11],[@R15]\]. PLDLLA-6TMC so far has only been investigated for degradation *in-vitro* (laboratory experimentation) and *in-vivo* (animals), not *in-situ* (patients) \[[@R11],[@R15]\].

2.. PATIENTS AND METHODS
========================

2.1.. Patients
--------------

Eighteen patients (12 women and 6 men) participated in this study and signed a detailed document of informed consent. Only patients who accepted the possible risks were included. Furthermore, our Institutional Review Board / Board of Ethics approved the protocol that we used to analyze the material, which was removed in the course of a secondary operation for local access to osteotomy of bone, e.g. in rhinoplasty or for augmentation. The patients were aged 16 to 46 years (24 years on average), and the primary operations (i.e. the implant placements) were carried out between April 2005 and April 2007. Treatment of patients was per ISO 9001:2000 and revised guidelines in the maxillofacial and plastic facial surgery unit.

2.2.. Implants
--------------

Within the total patient population, eighty patients had received a racemic random mix of Poly-70L mole%/24D Lmole%-lactide with 6mole% Trimethylenecarbonat (PLD-LLA-TMC; INION CPS^®^, INION OY, Tampere, Finland) 2.0mm system osteosyntheses, retaining maxillary or mandible fractures and osteotomies. Only 26 of the cases had secondary surgery as septorhinoplasty, chin plasty, alveolar process augmentation and dental implant insertion and required explantation during the secondary procedure.

All implanted material was FDA / CE / TÜV approved and certified (obligatory product marks for the US, European, and German markets, respectively, indicating compliance/certification with requirements specified in the American Consumer Safety Act, European Marketing Directive, and German Marketing Directive). Screws and plates were injection-molded (Fig. **[1](#F1){ref-type="fig"}**). As screws attached the plates to the bone and plates unite the fragments, screws and plates were always applied together in patients.

2.3.. Procedures
----------------

All osteofixations were performed using standard maxillary and mandibular procedures for osteotomies and fracture synthesis (Fig. **[2](#F2a){ref-type="fig"}, [a](#F2b){ref-type="fig"}-[c](#F2c){ref-type="fig"}**). After subperiosteal exposure and segment repositioning in the maxilla, 4--8-hole 2.0 mm system plates were fixed to both segments with 2--4 screws of 2.0× 6 mm dimensions. In the mandible 2.5 mm system was used in identical fashion at the same operation date.

Intraoperatively immersion for 60 s in a basin containing sterile water, at 55 °C, rendered the plate flexible after 5-7 s in their glass-transition temperature interval (50--70°C), to allow for adaptation to the shape of the bone. Using the 2.0 mm-strength system, screw-holes were drilled using a 1.75 mm-diameter burr, the thread was cut using a tap of 2.0 mm diameter thread-to-thread, and the 2.0 mm-diameter screw (diameter thread to thread) was inserted. Plates were 2.25 mm thick and 6 mm wide. In the 2.5 mm strength system, the burs had a diameter of 2.25 mm, the tapper 2.5 mm thread-to-thread and the screw that was inserted also had a diameter of 2.5 mm.

2.4.. Explantations
-------------------

All the patients underwent local biopsies and explanations of resorbable material at different times, Fig. (**[3](#F3a){ref-type="fig"}, [a](#F3a){ref-type="fig"}, [b](#F3b){ref-type="fig"}**), but only the 2.0 mm strength system L-shape-plates were analyzed: 21 explants retrieved from 12 women and 6 men; 16-46 y. The removal included local incision, dissection and exposure; then the implant was intentionally removed as much as needed for the augmentation or osteotomy. Therefore at times a fragment that was large enough to place in the bending apparatus was obtained. The harvested material was cleaned with water and dried with cotton swab before dry storage for use in laboratory examination.

After a minimum of 3 months *in-situ*, all the implants were intact before removal but broke readily during removal. The mechanical strain that occurred during explantation was caused by surgical isolation from the surrounding fibrous tissue, which can overstrain the residual bending strength of the plate. During surgery, when the complete implant and fibrous tissue were removed together, the implant broke when dissection from the surrounding tissue was ventured. Further exposure therefore could not be justified due to patient discomfort.

2.5.. Specimens
---------------

After removal of the explants from the patients, these specimens were stored dry without further loading, until the testing was performed.

In a previous report, we were unsuccessful in performing four-point bend tests on the removed implants, because either they were too small or had been bent during the primary procedure for clamping in the testing apparatus. \[[@R18]\]. In the present work, however, we were successful by using a modified smaller three-point bending apparatus and explants with a length above 8mm long. The set-up and testing was mainly performed to assess the fatigue performance of the explanted material and compare it to that of out-of package and laboratory-aged material (Fig. **[4](#F4a){ref-type="fig"}, [a](#F4a){ref-type="fig"}, [b](#F4b){ref-type="fig"}**).

For-point-bending tests result in comparison with three point bending tests in general in a lower strength due to the higher loaded or "critical" volume, which is tested in a four-point-bending test. Since the aim of the study is a comparison of different implants which was carried out on test samples of comparable shape on the same three point bending arrangement, the results of the study are not affected. In addition, four-point-bending tests were not feasible for the size of the samples.

2.6.. Fatigue Testing
---------------------

These tests were carried out using a stress amplitude that is lower than the yield strength of the implant material. In performing fatigue tests on osteosyntheses, two approaches may be taken. In the first, an osteofixation plate is attached with bone screws to a member whose properties are similar to those of cortical bone, and the plate is then loaded so that the stresses are the same as those seen physiologically. In the second approach, the fatigue performance of the implant material may be evaluated using a standard test set-up (three-point bending, tension-tension, compression-compression, etc.). Since mostly fragments of the explants were available in the present study, we utilized the second approach. Whereas the first approach gives some insight into the fatigue performance of an entire component (in this case the implant), the second approach yields some insight into the fatigue performance of the material. In our case, the latter approach is sufficient in order to assess the effect of the materials degradation on its fatigue performance.

The tests were carried out in demineralized water, at room temperature, using a commercially available servohydraulically-actuated universal materials testing machine (Mini-Bionix; MTS Systems GmbH, Berlin, Germany). The distance of the lower loading rollers of the three-point-bending set-up was 5 mm. A sinusoidal pulsating load (frequency = 5 Hz) starting value: F~0~ = 128 N, step width: ΔF = 13 N was applied in load control. The maximum number of load cycles (N~max~) that we used (150,000) is that typically used in fatigue testing of osteofixation plates used in cranio-maxillo-facial surgery \[[@R23]\]. Specimens which reached N~max~ = 150,000 cycles without failure were taken out of the experiments and classified as "run-outs". The peak value of the deflection of the test plate, after 500 loading cycles, was recorded. If this deflection exceeded 1 mm or if crack(s) were visible in the plate, the plate was considered to have failed.

The virgin (unimplanted) identical products used were 7-hole L-plates. They were cut to obtain specimens of the same size as the explanted implant fragments. The implants were cut such that a test specimen contained two holes. The upper loading roller exerted a force in the center of a strut connecting two holes. The implant rested on the two lower loading rollers, which were positioned near the center of the hole (Fig. **[4c](#F4c){ref-type="fig"}**). The specimen dimensions (virgin implants and explants) were generally: length 8 mm (distance of the support rollers: 5 mm), height 1.27 mm), width: 6.8 mm (Fig. **[4c](#F4c){ref-type="fig"}**).

Prior to testing, all the implants were soaked in water for 7 days in order to achieve an essentially complete saturation.

The testing was carried out using the staircase method given by Dixon and Mood. Fig. (**[5](#F5){ref-type="fig"}**) \[[@R24],[@R25]\]. This involved selecting an initial load F~0~ (preferably in the range where lifetimes just below n~max~ occur) and load step (ΔF). If run-out occurs at F~0~, increase the load by ΔF; if, however, the specimen fails at F~0~, decrease the load by ΔF. The testing gathers fatigue data at stress levels, which lie in the vicinity of the Median Fatigue Limit (MFL). The MFL was calculated according to the staircase method of Dixon and Mood, see references \[[@R24],[@R25]\].

The tests were conducted on specimens cut from the virgin products. Tests on the explant specimens were performed at a load at which run-out occurred for the former specimens, Figs. (**[6](#F6a){ref-type="fig"}**, **[7](#F7){ref-type="fig"}**).

2.7.. Morphological Examinations
--------------------------------

The morphologies of the virgin products and explants were obtained using a scanning electron microscope (Quanta 3G FEG; FEI, Eindhoven, The Netherlands), at magnifications ranging from 33 to 5500, Fig. (**[8](#F8){ref-type="fig"}**, **[9](#F9){ref-type="fig"}**, **[10](#F10){ref-type="fig"}**).

3.. RESULTS
===========

Twenty-one explants from different *in-situ* periods (2.5-6.0 month) were successfully harvested, but only 12 were of sufficient size for use in the fatigue tests. The structural integrity of explants harvested after 6 months *in situ* was very poor, making them mostly unsuitable for use in the fatigue test.

In the fatigue tests, the virgin products (9 segments) tested showed a Median Fatigue Limit (MFL) of 49 N ± 11 N and survived at 38 N (Fig. **[5](#F5){ref-type="fig"}**). At this load, all of the explant specimens tested failed (Fig. **[6a](#F6a){ref-type="fig"}**). When testing specimens of different volume, the critical volume of a tested specimen has to be considered, since it has an influence on the strength. In our case, we selected specimens of similar dimensions and essentially identical critical volume in order to assure a direct comparability of the results. At 38 N, there was a moderate drop in fatigue life of the explant with increase *in-situ* time up to about 4 months, after which the drop was very steep (Fig. **[6b](#F6b){ref-type="fig"}**). Fatigue test specimens fabricated from a point in an explant close to the L-shaped feature of the implant (that is, segments that were proximal to the osteotomy line, the area of maximum load *in-situ*) had a significantly shorter life than those fabricated from fragments taken farther from the osteotomy line (Fig. **[7](#F7){ref-type="fig"}**; p=0.0017). This trend is consistent with increase in stress as distance to osteotomy line decreases.

3.1. Morphological Examinations
-------------------------------

The surface of a virgin product was smooth, with traces of press flags arising from the melt joining performed as part of the manufacturing process (injection molding) (Fig. **[8](#F8){ref-type="fig"},[a](#F8){ref-type="fig"},[b](#F8){ref-type="fig"}**). On these surfaces, there were local cracks, which may have been caused by residual stresses during injection molding (Fig. **[8c](#F8){ref-type="fig"}**). Since these defects are under a flexural load in the vicinity of the neutral fiber, they most likely will not compromise the reliability of the implant,

The morphology of the fracture surface of fragments taken from an explanted implant varied with implant time *in situ*. After 4.5 months, with one exception, there was an absence of cracks running from the pores into the bulk of the implant (Fig. **[9a](#F9){ref-type="fig"}**). The exception is seen in the region close to the surface of the implant (i.e. close to the edge of the fracture surface: here, cavities were formed (Fig. **[9b](#F9){ref-type="fig"}**). After 9 mo, there were signs of severe internal degradation; the entire fracture surface shows cracks and pores which reach into the bulk of the implant (Fig. **[9](#F9){ref-type="fig"}, [c](#F9){ref-type="fig"}, [d](#F9){ref-type="fig"}**). This internal degradation resembles the surface-core degradation mechanism observed for "massive" poly(DL lactide) implants \[[@R26]\]. The development of the degradation features seen in the present explants agreed well the fatigue test results as well as the claims of the implant manufacturer that the mechanical strength of the implant is stable up to about 3 mo *in situ* \[[@R15]\]. The onset of the core degradation (as seen in Fig. **[9b](#F9){ref-type="fig"}**) will result in an initial decrease of the implant strength. A significant drop of the flexural strength will occur, if the internal degradation extends from the core of the implant (which does not contribute significantly to the strength due to its proximity to the neutral axis vicinity to the neutral fiber) to the implant surface. This occurs after *in situ* periods longer than 4 months. Fig. (**[10](#F10){ref-type="fig"}, [a](#F10){ref-type="fig"}, [b](#F10){ref-type="fig"}**) illustrates *in-vitro* laboratory-aging associated surface roughness and dimples on the surface of the implants, also at bigger magnification these irregularities were contrasting the smooth surfaces of *in-situ* aged explants.

4.. DISCUSSION
==============

PLDLLA-TMC has the advantage over previous copolymers to be more compliant and less brittle for an easier handling and more reliable clinical use (e.g. material has less tendency to break after only minute increase in torque as in other polymers, but the screws can be tightened with a slow long increase in torque until potential breakage). Moreover the 2.5 mm strength can be used in more complex fracture and osteotomy situations also. Yet the stability comes at the price of a large volume. Therefore degradation may be unreliable above all, as *in-vitro* laboratory, *in-vivo* animal studies cannot become transferred one-to-one to humans \[[@R18],[@R19]\].

4.1.. Fatigue Tests
-------------------

While all the virgin products in the present report showed run-out at 38N, all of the specimens fabricated from explants failed at this load level. For the explant specimens, although there was a trend of decreased failure load with increased *in-situ* time of the implants, this decrease was pronounced after 4 months *in situ*. Dry storage was chosen, as storage in aqueous medium would seriously accelerate degradation.

Several stability evaluations are published on the PLDLLA-6TMC material, which was evaluated within the present report. Nieminen *et al.* \[[@R15]\]. after subcutaneous implantation into sheep, explanted plates to find them to maintain their tensile strength for minimum 6 weeks. The maximum strength of the plates in 3-point bending tests diminishes gradually by 87% in 26 weeks. These results concord with our observations: up to 3-4 months *in-situ*, only a moderate fatigue strength reduction occurred (partially caused by *in situ*mechanical loading, partially caused by the onset of degradation); at 6 months*in situ*, severe loss of mechanical strength and significant internal degradation were observed. Although implants did not loose their shape after 6 months *in-situ*, fragmentation onset and increasing rate of material loss can be expected, which ultimately results in significant bulk degradation. The latter is a "skin-core-differentiation", when degradation products accelerate degradation inside the implant, while surface material can become metabolized locally. This was observed in the scanning electron microscopy for the implants 9 months *in-situ* \[[@R17]\].

This present report affirmed other successful investigations on the mechanical performance of new and explanted resorbable implants \[[@R18],[@R27]\]. Yet previous studies showed a tendency to higher recrystallization in *in-situ* aged versus *in-vitro* aged specimen (who by themselves were immersed in physiological buffer solution at 37°C). This was interpreted to be an effect of permanent intermittent loading. Therefore within the present study, a different approach was undertaken, determining the median fatigue limit of new implants with the staircase method. And as it was expected, explants showed a shorter fatigue life after three months *in-situ* compared with new implants.

Longer periods *in-situ* correlated with a shorter fatigue life and the effect became visible only after an implantation period of 3 months. This is an indication that initial retention strength is maintained during the first three critical months of bone healing. Resorption and mechanical loading during implantation, implantation period *in-situ*, and explantation will contribute to the loss of fatigue strength. Local variations of the fatigue strength of individual explants were observed, either due to initial variations of the materials strength or due to variations of the stresses *in vivo*. Initial variation in material strength was not found in the out-of-package samples therefore can be disregarded. In the clinical situation a complex mechanical loading of the implant occurs, which results in an inhomogeneous stress distribution. Close to the osteotomies and in the vicinity of specific geometric features of the implant (e.g. narrow connections or angular shape), stress concentrations will occur, which result in a higher probability of failure in these regions.

Buijs *et al.* \[[@R13],[@R14]\]. investigate seven biodegradable and 2 titanium osteofixation systems. Plates and screws were fixed to 2 polymethylmethacrylate (PMMA) blocks to simulate bone segments. Plates and screws were subjected to tensile, side bending, and torsion tests. During tensile tests, strength of the osteofixation system was monitored; stiffness calculated for the tensile, side bending, and torsion tests. The 2 titanium systems (1.5 mm and 2.0 mm) are reported to evince significantly higher tensile strength and stiffness compared with 7 biodegradable systems (2.0 mm, 2.1 mm, and 2.5 mm). The 2.0 mm titanium system showed significantly higher side bending and torsion stiffness than the other 8 systems. It is concluded that the titanium osteofixation systems were (significantly) stronger and stiffer than the biodegradable systems. The BioSorb FX^®^ (Linvatec Biomaterials Ltd, Tampere, Finland), LactoSorb^®^ (Walter Lorenz Surgical Inc, Jacksonville, FL), and Inion CPS^®^ 2.5 mm systems however show high mechanical device strength and stiffness. Resorb X^®^ (KLS Martin GmbH & Co, Tuttlingen, Germany) and MacroPore^®^ (MacroPore Biosurgery Inc, Memphis, TN) systems present as the least strong and stiff systems. A prospective evaluation could compare this present study's findings with titanium plate *explants* and compare these to titanium *out -- of -- package specimen*. Minimal decrease of retention strength should be expected in titanium (not mentioning the unfortunate drawbacks of titanium plates) \[[@R28]-[@R35]\]. Vaananen *et al.* \[[@R11]\]. examine the hydrolytic stability of an ankle plate made from identical material over 12 weeks. A fracture of the lateral malleolus is simulated, and the parameters of cyclic loading chosen representing the physiological conditions during the healing period. Additionally, the effect of cyclic loading on degradation is investigated by measuring the inherent viscosity. In group I, the cyclic loading is conducted in four phases with gradual increments in estimated walking distance and speed during the healing period. In group II, cyclic loading is conducted after 12 weeks. Group III is used as a control for inherent viscosity measurements \[[@R18]\]. None of the specimens failed, no significant differences are found between the loaded groups in any of the parameters, no significant differences are found in inherent viscosities at 12 weeks. The initial fixation stability provided by the biodegradable ankle plate remains biomechanically unchanged over 12 weeks. Cyclic loading, applied either during, or after 12 weeks of hydrolytic degradation, does not appear having any clinically relevant effect on the fixation stability or the degradation properties. The present study confirmed flexural fatigue strength to only decrease after three months *in-situ*. However the *in-vitro* aging process cannot represent the *in-situ* (*in-patient*) situation. Although an elaborate approximation, loading does not correspond to the permanent intermittent complex loading that occurs *in-situ*. The loading patterns chosen by Vaananen \[[@R11]\]. are possibly representative for the loading situation of a plate used for fixation in the leg, but is certainly not applicable to the jaw, as permanent movement in swallowing of saliva and speaking occurs, even if no loading by hard food chewing occurs. Moreover the effect of enzymes, cell cytotoxicity and variation in loading are not sufficiently represented. The present report included these factors within the *in-situ* aging, as these factors cannot become reproduced in the laboratory.

4.2.. Degradation
-----------------

Nieminen *et al.* \[[@R15]\] test the tissue reactions of the degrading identical PLDLLA-6TMC material. To the mandible and dorsal subcutis of 12 sheep, plates and screws are implanted. The animals are sacrificed at 6-156 weeks, paraffin and methylmetacrylate techniques provide histologies. During follow-up, degradative and mechanical properties are measured of *in-vivo* and *in-vitro* implants. Upon light microscopy, *in-vivo* implant material begins to fragment at 52 weeks and cannot be detected at 104 weeks, which is at a point in time far later than the retrieval of the implants, studied in this work. Identical polymer implants have different patterns of resorption depending on e.g. local loading, perfusion, motion, temperature distribution that largely differs between dorsal subcutis and the craniofacial bones as between sheep and humans \[[@R19],[@R22]\]. This makes specific study of a certain polymer a necessity depending on these named factors as has been performed with this study.

We investigated fracture surfaces of explants by SEM, which fractured during the explantation process and detected severe signs of internal degradation after 6 months *in-situ*. This observation, however, gives little information on the time period *in-situ,* when a macroscopic fragmentation of the implants will occur. Nieminen *et al.* \[[@R15]\] see no significant foreign body reactions in the mandibles, which were confirmed by our patients, who within clinical use were n=80 receiving PLDLLA-TMC material, when none developed foreign body reactions that were clinically apparent. The dorsal subcutis of the sheep examined by Nieminen *et al.* \[[@R15]\]. disclosed mild reactions, which are, however, not of clinical significance. The implants *in vitro* maintain their entire mass for 26 weeks and lose 63-80% of the mass by week 104. Inherent viscosity of the implants *in vitro* and *in vivo* diminishes uniformly, screws retain their shear strength for 12-16 weeks. Many more studies regarding the hydrolysis of older poly(L-lactide-co-polyglycolide) (PLGA) copolymer chains *in-vitro* to degradable low-molecular-weight units, through water uptake into the implant body are to be found in the literature. *In-vivo* but [not]{.ul} *in-situ* in chinchilla rabbit femurs, PLGA complete degradation required 12 months \[[@R29],[@R36],[@R37]\]; in parietal craniotomies of rabbits 12 months \[[@R20]\]; and in minipigs 18 months. \[[@R10]\]. Differences in resorption times are probably due to different resorption mechanisms, depending on the species of laboratory animals. Furthermore, implant size, shape, molecular weight, composition, monomer conversion, macromolecular orientation and implant position in the body \[[@R19]\]. make in-patient location-specific assessment necessary. The combination of the copolymers PLLA for adequate strength and the less stable poly DL-lactic-acid (PDLLA) for fast, reliable degradation as poly(L-lactide-co-DL-lactide) (P(L/DL)LA) constitute together with PLGA available and clinically applied resorbable miniplate osteosyntheses today. Addition of trimethylenecarbonate to P(L/DL)LA --TMC provides higher elasticity i.e. a polymer that is less brittle as pure PLLA or P(L/DL)LA, which is advantageous in clinical handling \[[@R38]\].

Losken *et al.* \[[@R39]\] examine the degradation within 1 year and foreign body reaction and cyst formation evaluating the rate of similar biodegradation of "Inion CPS Baby"^®^ biodegradable plates and screws under different clinical circumstances in the rabbit craniofacial skeleton and evaluate their efficacy for use in pediatric craniofacial surgery. In these implants DL-PLLA has been replaced by PGA maintaining a similar TMC fraction, therefore direct comparison with the results of the present report is not possible. These implants are tested in a rabbit model: plates are applied to the frontal bone, over a bony defect of the parietal bone, to a nasal bone fracture, and inserted in the subcutaneous space over occipital bone in thirty 6-week-old rabbits. At 9 months, the plates and screws have effectively biodegraded no longer have retention power, which however is difficult to evaluate, as the cooking of paraffin embedding washes out residual poly-lactide. However fragmentation of the implant material was noted. Residual implant material was still present on gross and histological examination in rabbits at 9, 12, 15, and 18 months. Residue of a screw was still palpable in 1 rabbit at 18 months. There was no evidence of cyst formation in any of the examined specimens. Macrophages and giant cells were present in most specimens. The authors document a relatively short resorption time of (9 months) and normal inflammatory sequelae in an adult rabbit model and suggest that these plates may be used safely in fixing the pediatric craniofacial skeleton. A similar study could be performed with the INION CPS^®^ 2.0 and 2.5mm system material.

SEM images, acquired to support the evidence found in the mean fatigue strength showed marks of the production process; at 4 ½ months *in-situ*, slight effects of the degradation became visible and at 9 months *in situ* effects of degradation became clearly visible.

P(L/DL)LA examined earlier as well as the PLDLLA-6TMC implants are amorphous, despite the fact that the raw material granules have a crystallinity of around 10%. In PLLA, PLDLLA-6TMC and PLGA, hydrolysis precedes phagocytosis \[[@R7],[@R9],[@R40]\]. This should obviate bulky degradation and the accumulation of osmotically active polymer debris that induces local osteolysis in adjacent bone, which is beyond the absorptive capacity of the surrounding tissues. \[[@R7],[@R9],[@R40]\]. When chinchilla rabbit bone was examined under a light microscope, P(L/DL)LA implants were reported to have degraded fully and disappeared after 12 months \[[@R36]\]. Studies using sheep found no discharge or swelling after the 6-month follow-up \[[@R41]\].

*In-vitro* degradation, simulating spontaneous hydrolysis, cannot be compared to the *in-vivo* situation, the microclimate in which enzymatic degradation, recrystallization and phagocytosis occur, cannot be simulated by *in-vitro* studies and this has been confirmed with this study's unsuccessful assay of *in-vitro* aging. In addition, animal models cannot be compared, as in humans hydrolytic degradation predominates, while in animals (such as rabbits) cellular enzymatic processes play a more prominent role \[[@R36]\]. Interindividual degradation variability in patients and individual risk factors are not currently known with certainty. This study assesses, whether clinical in-patient degradation is reliable by fatigue testing and not inherent viscosity or cristallinity, which has been proven before for very similar polymers \[[@R18]\].

Differences in resorbable polymer osteofixations have been reported to result from several factors: their shape, the composition of the material used, molecular weight, monomer conversion, macromolecular orientation and the different animal models and body regions in which they are used \[[@R19],[@R36]\]. Therefore the *in-situ* results were compared with the *in-vitro* results \[[@R17],[@R18]\]. Clinical in-patient studies usually do not provide sufficiently long follow-up periods, and do not sufficiently consider side effects, reossification and palpability \[[@R4]\]. Also, these studies do not emphasize what really happens to the material *in-situ*, but instead draw conclusions based on indirect signs of degradation. For example when in animals-studies, polymers had completely resorbed and were not visible under light microscope, bur holes had yet not completely reossified. Radiological reossification, often used as clinical in-patient marker of degradation, may therefore be captious when determining complete resorption \[[@R36]\]. Until now, no degradation studies had been carried out *in-patients* to evaluate degradation kinetics and reliability directly from PLDLLA-6TMC explants as was done in the present study. Prior to the present study, degradation studies had not used explants to evaluate degradation kinetics and the reliability of decomposition in patients.

4.3.. Clinical Consequences and Limitations
-------------------------------------------

Laughlin *et al.* \[[@R16]\] clinically test resorbable plates with the identical polymer tested here versus titanium 2-mm plates regarding fracture healing, bone union and function. Fifty mandibular fractures are included being either mandibular body, symphysis, angle, or ramus fractures, requiring open reduction internal fixation. Data are compared with literature norms for titanium and nonrigid fixation data from a prospective study performed within the same institution. Clinical and radiographic evaluation indicated bone union at the eighth follow-up visit, 3(6%) sites had clinical signs of infection treated immediately upon presentation, with fracture union by 8 weeks. No revision surgery was required; 12 screw heads fractured during insertion, immediately replaced without significant fracture sequelae.

Vaananen *et al.* \[[@R12]\] develop a \"free-form\" osteofixation plate, equipped with pilot holes. The plate construction allows screw placement in optimal position. The screw heads are either countersunk into the plate or cut away. The plate further can be cut and contoured to match the bone. The mechanical properties of the freeform osteofixation plate made from the identical polymer are compared to the conventional biodegradable plate. Acrylic pipes fixed together with plates and screws are tested with tensile and cantilever bending to measure the fixation properties. The tensile test loads the samples with constant 5 mm/min speed until failure of fixation. Yield load, maximum failure load, and initial stiffness are recorded, and the failure mode visually determined. In cantilever bending test, samples are loaded with a constant speed of 50 mm/min (with a moment arm of 45mm) until failure of fixation. The yield bending moment and initial stiffness are recorded, and the failure mode determined. The results show the new free-form plate to provide fixation at least as strong as the tested conventional biodegradable plate. No clinically relevant difference is found between free-form plate fixation with countersunk screws and fixation with screws without heads.

A larger case number is planned in future evaluations. However, within a technology to avoid secondary procedures, this will require considerable time. Only large-scale long-term clinical research will ultimately show the optimum clinical biocompatibility and physico-chemical characteristics of biodegradable orthopedic implants \[[@R4]\].

4.4.. Conclusion
----------------

This study has shown that degrading PLDLLA-6TMC copolymer-implants do maintain their retention strength for three months and then decrease reliably*in-patients* and morphological results were consistent with those obtained in the fatigue test.
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![Shows the 7-hole-L-plate evaluated within this study and straight 4-hole-plate in 2.0mm strength, moreover a 2.0x6 mm screw.\
The straight 2.0 mm system plate as the 2.5 mm system plates and screws were not biomechanically evaluated in this report.](TOBEJ-7-133_F1){#F1}

![Photograph of a PLDLLA-TMC (arrow) osteofixation in a mandible fracture case.](TOBEJ-7-133_F2a){#F2a}

![Photograph of maxillary osteosyntheses after Le Fort I advancement (arrows).](TOBEJ-7-133_F2b){#F2b}

![Photograph of the identical osteofixations (arrows) after three months at the secondary surgery of alveolar process augmentation. Due to the incipient hydrolysis the screws and plates appear opaque.](TOBEJ-7-133_F2c){#F2c}

![Photograph of "L-shape-plate" explants after 3 months in-situ, where the injection-molded screws of 2.0mm diameter show more opacity. Size of the implant and material composition affect both degradation behavior, the latter can be ruled-out as the polymer is identical. Moreover at the inferior left corner, a 2.5 mm-system screw shows lower opacity probably due to her bigger diameter and volume that per-mits only slower hydrolysis as in the 2.0 mm screws.\
Upon removal the L-plates were cut at their knee, as such three-hole fragments could easily be positioned in the fatigue test set-up.](TOBEJ-7-133_F3a){#F3a}

![Photographs of explants evincing progression of opacity as a sign of hydrolysis within the implant after 5 months, also affecting the plate fragments at this stage. Three-point bending testing beyond 6 months in-situ was impossible, as explants broke too easily into small pieces upon removal or handling. The resulting fragments could no longer become fitted into the fatigue test set-up.](TOBEJ-7-133_F3b){#F3b}

![Photograph of an explant specimen positioned in the three-point bending test set-up. The mechanical tests were carried out at room temperature, the explants were conditioned in deminer-alized water at 37°C for one week.](TOBEJ-7-133_F4a){#F4a}

![Sketch of a 3-point-bending test set-up.](TOBEJ-7-133_F4b){#F4b}

![Specimen for 3-point-bending experiments. The upper loading roller exerted the pulsatile sinusoidal force in the center between two holes (yellow line). The specimen rested on the lower loading rollers at the positions marked with red lines.](TOBEJ-7-133_F4c){#F4c}

![Results of the fatigue tests on virgin products with a run-out level of 38 N, MFL: 49 N ± 11 N. This means at 38 N all out-of-package specimens survived 150,000 load cycles, at loads above 38 N failures occurred.](TOBEJ-7-133_F5){#F5}

![Results of the fatigue tests on virgin products (+: failures, О: run-outs) and explanted implants (all failures; \*:6 months in-situ, ⋄: 4 months in-situ, r∆: 3 months in-situ, □: 2.5 months in-situ).\
All explants did fail at the F = 38 N level and the implantation period correlates with reduction in life-time within the fatigue strength exami-nation.\
Solid line: regression line including +, О, blue dashed line: 95% confidence interval for the regression line, red dashed line: 95% prediction interval, i.e. an additional measurement at a force level will lie with 95% probability within this prediction interval. The result for the implant 6 months in situ (\*­) lies outside of the prediction interval, as a result the degradation resulted in a significant decrease of its fatigue strength](TOBEJ-7-133_F6a){#F6a}

![Results of the fatigue tests on virgin products and explanted implants (green symbols), carried out at 38 N related to the in-situ time\
A moderate drop of the lifetime occurs between 2.5 - 4 months, a significant drop in strength after 6 months. For fractures of the explants, the mean values and standard deviation are plotted. For the run-out level of the new implants, the results of the linear regression with F = 38 N and the \"wide\"confidence interval are shown instead of the mean value and the standard deviation](TOBEJ-7-133_F6b){#F6b}

![Results of the fatigue tests on virgin products (+: failures, О: run-outs) and explanted implants x: 6 *in situ* months, ⋄: *in situ* 4 months, ∆: *in situ* 3 months: influence of testing position on explants from which test specimens were taken. Open symbols: position 1, closed symbols: position 2. A t-test of 3 / 4 months *in-situ* explants measured at position 1 versus position 2 showed highly significant results (p=0.0017).](TOBEJ-7-133_F7){#F7}

![Fig. (8a). Morphology of the surface of a virgin implant, revealing a smooth appearance and traces of the processing as joining of the melt during injection molding.\
Fig. (8b). Is a new implant showing a local crack at the interface to the screwhole from the manufacturing process.\
Fig. (8c). A local crack at the interface of a virgin product, possibly caused by residual stresses after cooling. The position of the crack is most likely uncritical (within neutral fiber).](TOBEJ-7-133_F8){#F8}

![Fig. (9a). Fracture surface of a fragmented implant explanted after 4.5 months *in situ* (X 50).\
Fig. (9b). Fracture surface of a fragmented implant explanted after 4.5 months *in situ* (X 5000).\
Fig. (9c). Cavities form below the implant surface.\
Fig. (9d). Fracture surface of a fragmented implant explanted after 9 months *in situ*, showing pores and cavities in the implant body, a consequence of hydrolysis.](TOBEJ-7-133_F9){#F9}

![Fig. (10a). REM reveals *in-vitro* laboratory-aging associated surface roughness and dimples on the surface of the implants.\
Fig. (10b). At bigger magnification these irregularities were contrasting the smooth surfaces of *in-situ* aged explants.](TOBEJ-7-133_F10){#F10}
